192 related articles for article (PubMed ID: 36077548)
1. The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic Sclerosis.
Colasanti T; Stefanantoni K; Fantini C; Corinaldesi C; Vasile M; Marampon F; Di Luigi L; Antinozzi C; Sgrò P; Lenzi A; Riccieri V; Crescioli C
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077548
[TBL] [Abstract][Full Text] [Related]
2. Systemic sclerosis fibroblasts show specific alterations of interferon-γ and tumor necrosis factor-α-induced modulation of interleukin 6 and chemokine ligand 2.
Antonelli A; Fallahi P; Ferrari SM; Giuggioli D; Colaci M; Di Domenicantonio A; Ferri C
J Rheumatol; 2012 May; 39(5):979-85. PubMed ID: 22422499
[TBL] [Abstract][Full Text] [Related]
3. Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis.
Rabquer BJ; Tsou PS; Hou Y; Thirunavukkarasu E; Haines GK; Impens AJ; Phillips K; Kahaleh B; Seibold JR; Koch AE
Arthritis Res Ther; 2011 Feb; 13(1):R18. PubMed ID: 21303517
[TBL] [Abstract][Full Text] [Related]
4. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases.
Antonelli A; Ferrari SM; Giuggioli D; Ferrannini E; Ferri C; Fallahi P
Autoimmun Rev; 2014 Mar; 13(3):272-80. PubMed ID: 24189283
[TBL] [Abstract][Full Text] [Related]
5. Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition.
Corinaldesi C; Ross RL; Abignano G; Antinozzi C; Marampon F; di Luigi L; Buch MH; Riccieri V; Lenzi A; Crescioli C; Del Galdo F
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809279
[TBL] [Abstract][Full Text] [Related]
6. Prostaglandin I(2) analogues enhance already exuberant Th17 cell responses in systemic sclerosis.
Truchetet ME; Allanore Y; Montanari E; Chizzolini C; Brembilla NC
Ann Rheum Dis; 2012 Dec; 71(12):2044-50. PubMed ID: 22814427
[TBL] [Abstract][Full Text] [Related]
7. Dissecting the Cellular Mechanism of Prostacyclin Analog Iloprost in Reversing Vascular Dysfunction in Scleroderma.
Tsou PS; Palisoc PJ; Flavahan NA; Khanna D
Arthritis Rheumatol; 2021 Mar; 73(3):520-529. PubMed ID: 33001586
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosis.
Akamata K; Asano Y; Taniguchi T; Yamashita T; Saigusa R; Nakamura K; Noda S; Aozasa N; Toyama T; Takahashi T; Ichimura Y; Sumida H; Tada Y; Sugaya M; Kadono T; Sato S
Rheumatology (Oxford); 2015 Jul; 54(7):1308-16. PubMed ID: 25539827
[TBL] [Abstract][Full Text] [Related]
9. Essential involvement of cross-talk between IFN-gamma and TNF-alpha in CXCL10 production in human THP-1 monocytes.
Qi XF; Kim DH; Yoon YS; Jin D; Huang XZ; Li JH; Deung YK; Lee KJ
J Cell Physiol; 2009 Sep; 220(3):690-7. PubMed ID: 19472212
[TBL] [Abstract][Full Text] [Related]
10. Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts.
Brembilla NC; Montanari E; Truchetet ME; Raschi E; Meroni P; Chizzolini C
Arthritis Res Ther; 2013 Oct; 15(5):R151. PubMed ID: 24289089
[TBL] [Abstract][Full Text] [Related]
11. Iloprost Attenuates Oxidative Stress-Dependent Activation of Collagen Synthesis Induced by Sera from Scleroderma Patients in Human Pulmonary Microvascular Endothelial Cells.
Giordo R; Thuan DTB; Posadino AM; Cossu A; Zinellu A; Erre GL; Pintus G
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443317
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a second receptor for prostacyclin on human airway epithelial cells that mediates inhibition of CXCL9 and CXCL10 release.
Wilson SM; Sheddan NA; Newton R; Giembycz MA
Mol Pharmacol; 2011 Mar; 79(3):586-95. PubMed ID: 21173040
[TBL] [Abstract][Full Text] [Related]
13. The safety and persistence of intravenous iloprost in systemic sclerosis.
Martins P; Dourado E; Fonseca JE; Romão V; Resende C
ARP Rheumatol; 2022; 1(2):122-128. PubMed ID: 35810370
[TBL] [Abstract][Full Text] [Related]
14. Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.
Antonelli A; Ferrari SM; Fallahi P; Piaggi S; Paolicchi A; Franceschini SS; Salvi M; Ferrannini E
Metabolism; 2011 Feb; 60(2):277-83. PubMed ID: 20206950
[TBL] [Abstract][Full Text] [Related]
15. Iloprost modulates the immune response in systemic sclerosis.
D'Amelio P; Cristofaro MA; D'Amico L; Veneziano L; Roato I; Sassi F; Bisignano G; Saracco M; Pellerito R; Patanè S; Ferracini R; Pescarmona GP; Isaia GC
BMC Immunol; 2010 Dec; 11():62. PubMed ID: 21159177
[TBL] [Abstract][Full Text] [Related]
16. Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis.
Raschi E; Privitera D; Bodio C; Lonati PA; Borghi MO; Ingegnoli F; Meroni PL; Chighizola CB
Arthritis Res Ther; 2020 Nov; 22(1):265. PubMed ID: 33168071
[TBL] [Abstract][Full Text] [Related]
17. Human cell-based anti-inflammatory effects of rosiglitazone.
Sottili M; Filardi T; Cantini G; Cosmi L; Morano S; Luconi M; Lenzi A; Crescioli C
J Endocrinol Invest; 2022 Jan; 45(1):105-114. PubMed ID: 34170488
[TBL] [Abstract][Full Text] [Related]
18. Fli1 Deficiency Induces CXCL6 Expression in Dermal Fibroblasts and Endothelial Cells, Contributing to the Development of Fibrosis and Vasculopathy in Systemic Sclerosis.
Taniguchi T; Asano Y; Nakamura K; Yamashita T; Saigusa R; Ichimura Y; Takahashi T; Toyama T; Yoshizaki A; Sato S
J Rheumatol; 2017 Aug; 44(8):1198-1205. PubMed ID: 28507181
[TBL] [Abstract][Full Text] [Related]
19. The Contribution of LIGHT (TNFSF14) to the Development of Systemic Sclerosis by Modulating IL-6 and T Helper Type 1 Chemokine Expression in Dermal Fibroblasts.
Ikawa T; Ichimura Y; Miyagawa T; Fukui Y; Toyama S; Omatsu J; Awaji K; Norimatsu Y; Watanabe Y; Yoshizaki A; Sato S; Asano Y
J Invest Dermatol; 2022 Jun; 142(6):1541-1551.e3. PubMed ID: 34838790
[TBL] [Abstract][Full Text] [Related]
20. Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis.
Antonelli A; Ferri C; Fallahi P; Colaci M; Giuggioli D; Ferrari SM; Frascerra S; Franzoni F; Galetta F; Ferrannini E
J Rheumatol; 2008 Sep; 35(9):1809-11. PubMed ID: 18709691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
